Mariel Paez‐Reyes
Research Subjects
Mariel Paez‐Reyes has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Diego A Mares‐Mateos
AlergiaMx Mexico City Mexico
1 shared publication - Jimena Prieto‐Gomez
AlergiaMx Mexico City Mexico
1 shared publication - Paola de Baro Alvarez
AlergiaMx Mexico City Mexico
1 shared publication - Ricardo Martinez‐Tenopala
AlergiaMx Mexico City Mexico
1 shared publication - Sebastian Moreno‐Castro
AlergiaMx Mexico City Mexico
1 shared publication - Victor Gonzalez-Uribe
AlergiaMx, Benito Juarez, Mexico City, Mexico; Facultad Mexicana de Medicina, Universidad La Salle Mexico, Tlalpan, Mexico City, Mexico
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (10)
Allergen Immunotherapy and 36‐Month Allergic Respiratory Disease Trajectories: A Target‐Trial
Background: Allergen immunotherapy (AIT) may modify allergic respiratory disease, but its association with progression and remission in routine practice remains uncertain. Materials and Methods: We emulated a target trial in a single‐center retrospective cohort at AlergiaMx, Mexico City, using data from 2020 to 2025. We compared sublingual allergen immunotherapy initiation within a 14‐day grace period with non‐initiation among AIT‐eligible patients. Follow‐up extended up to 36 months, and propensity‐score overlap weighting addressed baseline confounding. Results: Among 2,713 patients, 1,971 initiated AIT and 742 did not. Weighted disease worsening was 46.3% versus 63.6% (relative risk [RR] 0.73, 95% confidence interval [CI] 0.65–0.82), and sustained progression was 8.4% versus 17.0% (RR 0.49, 95% CI 0.35–0.69). At 36 months, clinical remission was 47.0% versus 18.3% (RR 2.57, 95% CI 1.93–3.43), and treatment‐associated remission was 31.7% versus 5.8% (RR 5.44, 95% CI 3.23–9.16). Longitudinal differences favored AIT for asthma control, quality of life, and fractional exhaled nitric oxide. Discussion: AIT initiation was associated with less worsening, greater remission, and favorable clinical and inflammatory trajectories over 36 months. These observational findings do not establish a causal disease‐modifying effect; residual confounding and differential follow‐up remain possible.
- 26 October 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (10)
Open AccessAllergen Immunotherapy and 36‐Month Allergic Respiratory Disease Trajectories: A Target‐Trial
Background: Allergen immunotherapy (AIT) may modify allergic respiratory disease, but its association with progression and remission in routine practice remains uncertain. Materials and Methods: We emulated a target trial in a single‐center retrospective cohort at AlergiaMx, Mexico City, using data from 2020 to 2025. We compared sublingual allergen immunotherapy initiation within a 14‐day grace period with non‐initiation among AIT‐eligible patients. Follow‐up extended up to 36 months, and propensity‐score overlap weighting addressed baseline confounding. Results: Among 2,713 patients, 1,971 initiated AIT and 742 did not. Weighted disease worsening was 46.3% versus 63.6% (relative risk [RR] 0.73, 95% confidence interval [CI] 0.65–0.82), and sustained progression was 8.4% versus 17.0% (RR 0.49, 95% CI 0.35–0.69). At 36 months, clinical remission was 47.0% versus 18.3% (RR 2.57, 95% CI 1.93–3.43), and treatment‐associated remission was 31.7% versus 5.8% (RR 5.44, 95% CI 3.23–9.16). Longitudinal differences favored AIT for asthma control, quality of life, and fractional exhaled nitric oxide. Discussion: AIT initiation was associated with less worsening, greater remission, and favorable clinical and inflammatory trajectories over 36 months. These observational findings do not establish a causal disease‐modifying effect; residual confounding and differential follow‐up remain possible.